GLP-R3 (Retatrutide) is an investigational triple-agonist peptide currently being studied for its potential metabolic effects. It is designed to simultaneously activate three hormone receptors involved in energy regulation and metabolism: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Because of this multi-pathway activity, Retatrutide has gained significant interest in metabolic and obesity research.
This compound is supplied strictly for laboratory research purposes and is not intended for human or veterinary use, diagnosis, or treatment. Tested in the United States 🇺🇸
